| 查看: 1803 | 回复: 101 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
生物学308求调剂（一志愿华东师大）
已经有6人回复
-
调剂求收留
已经有7人回复
-
272分材料子求调剂
已经有36人回复
-
275求调剂
已经有8人回复
-
一志愿211，化学学硕，310分，本科重点双非，求调剂
已经有20人回复
-
070300化学学硕311分求调剂
已经有19人回复
-
材料与化工调剂
已经有13人回复
-
材料与化工调剂
已经有33人回复
-
复试调剂
已经有7人回复
-
一志愿哈工大 085600 277 12材科基求调剂
已经有17人回复
» 抢金币啦！回帖就可以得到:
-
济南大学前沿交叉科学研究院2026年化学/化工专业硕士研究生调剂招生
+1/91
-
宁波大学2026年紧急补招植保方向（昆虫或植病）博士研究生1-2名
+1/88
-
征位互相欣赏、双向奔赴、同甘共苦、安度余生的伴侣
+1/75
-
福建农林大学材料工程学院高分子材料课题组还有少量学硕/专硕招生名额
+1/72
-
山东大学杨再兴课题组长期诚聘博士后
+2/64
-
大湾区大学李红庚课题组招聘研究助理
+1/35
-
B区调剂 兰州交通大学材料学院调剂
+1/20
-
河北大学燕麦基因组学与分子育种课题组招收2026级考研调剂生
+1/18
-
北华大学林产化学加工工程学硕和材料与化工专硕调剂招生
+1/11
-
深圳理工大学李进课题组招收科研助理/访问学生
+1/11
-
082200，085606，085606
+1/7
-
海南大学徐月山老师招生第二批博士名额1个，2026年9月份入学（高端设备开发方向）
+1/6
-
中国科学院城市环境研究所与福建农林大学联合培养研究生调剂公告（第一批）
+1/5
-
吉林工程技术师范学院 材料与化工 （0856） 招收调剂
+1/5
-
长江师范学院化学化工学院化学工程方向接收大量调剂考生
+1/4
-
华北理工大学矿物加工工程方向接收调剂研究生
+1/4
-
一志愿211电子信息347求调剂
+1/4
-
齐齐哈尔大学李莉课题组诚招2026级考研调剂生（学硕和专硕）
+1/4
-
江西科技师范大学申亮组招研究生（高分子化学专业）
+1/2
-
武汉纺织大学材料学院姜伟杰青团队招生
+1/2
86楼2015-11-20 16:22:10
简单回复
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
